Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 6Completed 4Active not recruiting 3Not yet recruiting 2

Sponsor Class

OTHER 2OTHER_GOV 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Lymphoid 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Lymphoma, B-Cell, Marginal Zone 1Inflammatory Breast Neoplasms 1

Interventions

pembrolizumab 66Cyclophosphamide 44Cisplatin 43Nivolumab 36Paclitaxel 32Carboplatin 31Radiotherapy 29Gemcitabine 28Docetaxel 25Dexamethasone 22atezolizumab 21Doxorubicin 19Bevacizumab 19Magnetic Resonance Spectroscopy 17fludarabine 16Vincristine 16Lenalidomide 16Etoposide 16Radiosurgery 15Letrozole 15Ipilimumab 15Fluorouracil 15Blood Specimen Collection 15palbociclib 14Rituximab 14Radiation 14Leucovorin 14Cytarabine 14Surveys and Questionnaires 13Specimen Handling 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Epirubicin × 90 days × Clear all
NCT00872625 2026-04-23

Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer

Centre Antoine Lacassagne

Phase 1 Completed
26 enrolled
Breast

Breast Neoplasms

NCT04433156 2026-04-09

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Henan Cancer Hospital

Phase 2 Completed
26 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT04877821 2026-04-02

NeoSACT

Guangdong Provincial People's Hospital

Phase 2 Completed
29 enrolled
Breast

Triple Negative Breast Neoplasms

NCT00066443 2026-03-27

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Canadian Cancer Trials Group

Phase 1/2 Completed
93 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡